If you step back and look at the state of biotech three-quarters into the year, here is what you see: an industry that is humming along, outpacing the S&P by a healthy margin, setting IPO records, and showering startups with cash. As for everyone’s worst fears — President’s Trump’s drug-pricing rants blowing up everything, for instance — they haven’t come to pass.
That’s all great. But what’s the view from the perspective of individual biotech companies?
Last January, I compiled a list of “burning questions” facing certain biotechs heading into 2018. Revisiting the list eight months later reveals a mixed bag of triumphs, pratfalls, and some continuing uncertainty. Here’s a look at my earlier questions — and updated answers.
What is cost for subscription after trial period ends? Is it per person, per company etc? We are a small company (<25 ppl, of which maybe 2 of us would read it).
Comments are closed.